Melbourne Consensus Offers Framework and Expert Guidance on Pancreatic Fat Accumulation

A new international consensus paper in Nature Reviews Gastroenterology & Hepatology lays out a shared conceptual framework for understanding intrapancreatic fat deposition—fat that accumulates within the pancreas—and offers expert guidance for how clinicians and researchers should study it. Dubbed the “Melbourne consensus,” the work targets a key problem in the field: inconsistent terminology, variable measurement approaches, and uncertainty about how best to interpret pancreatic fat in relation to disease risk.

The authors emphasize that intrapancreatic fat is not merely an imaging curiosity. It is thought to intersect with metabolic dysfunction, including insulin resistance and obesity-related pathways, and may influence pancreatic structure and function over time. However, the consensus notes that current evidence is heterogeneous, spanning different populations, imaging modalities, and clinical study designs.

A central goal of the framework is to clarify what “intrapancreatic fat deposition” actually means in practice. The paper describes how fat accumulation can be quantified directly through imaging-based metrics, and how such measures should be reported with sufficient detail to enable comparisons across studies. It also highlights the importance of standardizing study protocols, including the use of comparable acquisition settings and analysis strategies.

On the research side, the consensus outlines how to link pancreatic fat measurements to outcomes such as pancreatic exocrine and endocrine performance, diabetes incidence, progression of metabolic disease, and broader clinical endpoints. The authors argue that observational findings must be interpreted carefully, because pancreatic fat may reflect underlying systemic metabolic state rather than a purely local process.

Crucially, the Melbourne consensus also discusses the potential clinical implications for risk stratification. If pancreatic fat can be validated as a reproducible biomarker, it could help identify individuals at elevated risk for pancreatic dysfunction or metabolic deterioration earlier than traditional markers.

Still, the authors caution against premature clinical adoption. They call for stronger prospective studies and improved reproducibility, including clear definitions of patient inclusion criteria and rigorous control of confounders such as body mass, liver fat, medications, and comorbid conditions.

Finally, the paper serves as a roadmap for future work. By aligning how intrapancreatic fat is conceptualized and measured, the consensus aims to accelerate research translation—turning an emerging imaging signal into a more actionable, mechanistically grounded marker.